Inhibition of potassium channels in critical illness

Current Opinion in Anaesthesiology

Volumn 21, Issue 2, 2008, Pages 105-110

  Lange, Matthias ^a   Morelli, Andrea ^b   Westphal, Martin ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Refractory arterial hypotension; Sepsis; Septic shock; Sulfonylureas; Vascular hyporesponsiveness

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLIBENCLAMIDE; GLIPIZIDE; HMR 1402; HYPERTENSIVE AGENT; NORADRENALIN; POTASSIUM CHANNEL; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT;

CRITICAL ILLNESS; DRUG EFFECT; HEMODYNAMICS; HUMAN; HYPOTENSION; MUSCLE CELL; NONHUMAN; POTASSIUM CHANNELOPATHY; PRIORITY JOURNAL; REVIEW; SEPSIS; VASCULAR SMOOTH MUSCLE; ANIMAL; DRUG ANTAGONISM; PHYSIOLOGY;

ANIMALS; CRITICAL ILLNESS; HUMANS; KATP CHANNELS; POTASSIUM CHANNEL BLOCKERS; SEPSIS;

EID: 43249098434     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e3282f3ad74     Document Type: Review

References (60)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554.
3. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95:1122-1125.
4. Taylor BS, Geller DA. Molecular regulation of the human inducible nitric oxide synthase (iNOS) gene. Shock 2000; 13:413-424.
5. Annane D, Sebille V, Troche G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283:1038-1045.
6. Landry DW, Oliver JA. The ATP-sensitive K+ channel mediates hypotension in endotoxemiaand hypoxic lactic acidosis in dog. J Clin Invest 1992; 89:2071-2074.
7. Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003; 107:2313-2319.
8. Bakker J, Grover R, McLuckie A, et al. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72h can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004; 32:1-12.
9. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebocontrolled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30.
10. Annane D, Sebille V, CharpentierC, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871.
11. Morelli A, Lange M, Ertmer C, et al. Glibenclamide dose response in patients with septic shock: effects on norepinephrine requirements, cardiopulmonary
12. performance, and global oxygen transport. Shock 2007; 28:530-535. This prospective, randomized, double-blind study tested the effects of different doses of enterally administered glibenclamide, a sulfonylurea and KATP potassium channel blocker, in 30 patients with septic shock. Glibenclamide in doses of 10-30mg failed to counteract arterial hypotension or reduce norepinephrine requirements.
13. Warrillow S, Egi M, Bellomo R. Randomized, double-blind, placebo-controlled crossover pilot study of a potassium channel blocker in patients with septic shock. Crit Care Med 2006; 34:980-985.
14. This study tested the effects of 20 mg enteral glibenclamide in patients with septic shock. Glibenclamide failed to increase arterial blood pressure and thus reduce norepinephrine doses.
15. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995; 268:C799-C822.
16. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345:588-595.
17. Ashcroft SJ, Ashcroft FM. Properties and functions of ATP-sensitive K-channels. Cell Signal 1990; 2:197-214.
18. Buckley JF, Singer M, Clapp LH. Role of KATP channels in sepsis. Cardiovasc Res 2006; 72:220-230.
19. ATP channels and their potential pathophysiologcial role in sepsis.
20. Noma A. ATP-regulated K+ channels in cardiac muscle. Nature 1983; 305:147-148.
21. Dart C, Standen NB. Activation of ATP-dependent K+ channels by hypoxia in smooth muscle cells isolated from the pig coronary artery. J Physiol 1995; 483:29-39.
22. Davies NW. Modulation of ATP-sensitive K+ channels in skelet al. muscle by intracellular protons. Nature 1990; 343:375-377.
23. Keung EC, Li Q. Lactate activates ATP-sensitive potassium channels in guinea pig ventricular myocytes. J Clin Invest 1991; 88:1772-1777.
24. Ince C, Sinaasappel M. Microcirculatory oxygenation and shunting in sepsis and shock. Crit Care Med 1999; 27:1369-1377.
25. Jarrar D, Chaudry IH, Wang P. Organ dysfunction following hemorrhage and sepsis: mechanisms and therapeutic approaches (Review). Int J Mol Med 1999; 4:575-583.
26. Quayle JM, Nelson MT, Standen NB. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 1997; 77:1165-1232.
27. Sakai K, Saito K, Akima M. Synergistic effect of calcitonin gene-related peptide on adenosine-induced vasodepression in rats. Eur J Pharmacol 1998; 344:153-159.
28. O'Brien AJ, Thakur G, Buckley JF, et al. The pore-forming subunit of the K (ATP) channel is an important molecular target for LPS-induced vascular hyporeactivity in vitro. Br J Pharmacol 2005; 144:367-375.
29. Wu CC, Thiemermann C, Vane JR. Glibenclamide-induced inhibition of the expression of inducible nitric oxide synthase in cultured macrophages and in the anaesthetized rat. Br J Pharmacol 1995; 114:1273-1281.
30. Bryan J, Aguilar-Bryan L. Sulfonylurea receptors: ABC transporters that regulate ATP-sensitive K (+) channels. Biochim Biophys Acta 1999; 1461:285-303.
31. Teramoto N. Physiological roles of ATP-sensitive K+ channels in smooth muscle. J Physiol 2006; 572:617-624.
32. ATP channles.
33. Yan FF, Casey J, Shyng SL. Sulfonylureas correct trafficking defects of disease-causing ATP-sensitive potassium channels by binding to the channel complex. J Biol Chem 2006; 281:33403-33413.
34. Koster JC, Sha Q, Nichols CG. Sulfonylurea and K (+)-channel opener sensitivity of K (ATP) channels. Functional coupling of Kir6. 2 and SUR1 subunits. J Gen Physiol 1999; 114:203-213.
35. Asfar P, Ivanyi Z, Bracht H, et al. HMR1402, a potassium ATP channel blocker during hyperdynamic porcine endotoxemia: effects on hepato-splanchnic oxygen exchange and metabolism. Intensive Care Med 2004; 30:957-964.
36. Lange M, Szabo C, Van Aken H, et al. Short-term effects of glipizide (an adenosine triphosphate-sensitive potassium channel inhibitor) on cardiopulmonary hemodynamics and global oxygen transport in healthy and endotoxemic sheep. Shock 2006; 26:516-521.
37. In this experimental study, the transient reversal of endotoxin-induced vasodilation in sheep was achieved by bolus infusion of the sulfonylurea and KATP channel inhibitor glipizide. The water solubility of the compound was improved by converting it into a sodium salt.
38. Sorrentino R, d'Emmanuele di Villa Bianca R, Lippolis L, et al. Involvement of ATP-sensitive potassium channels in a model of a delayed vascular hyporeactivity induced by lipopolysaccharide in rats. Br J Pharmacol 1999; 127:1447-1453.
39. Vanelli G, Hussain SN, Aguggini G. Glibenclamide, a blocker of ATP-sensitive potassium channels, reverses endotoxin-induced hypotension in pig. Exp Physiol 1995; 80:167-170.
40. Gardiner SM, Kemp PA, March JE, Bennett T. Regional haemodynamic responses to infusion of lipopolysaccharide in conscious rats: effects of pre or posttreatment with glibenclamide. Br J Pharmacol 1999; 128:1772-1778.
41. Lange M, Williams W, Bone HG, et al. Continuously infused glipizide reverses the hyperdynamic circulation in ovine endotoxemia. Shock 2007; 27:701-706.
42. This experimental study indicates that a long-term reversal of endotoxin-induced vasodilation in sheep can be accomplished by continuous infusion of the sulfonylurea glipizide.
43. Domoki F, Perciaccante JV, Veltkamp R, et al. Mitochondrial potassium channel opener diazoxide preserves neuronal-vascular function after cerebral ischemia in newborn pigs. Stroke 1999; 30:2713-2718; discussion 2718-2719.
44. Sato T, Nishida H, Miyazaki M, Nakaya H. Effects of sulfonylureas on mitochondrial ATP-sensitive K+ channels in cardiac myocytes: implications for sulfonylurea controversy. Diabetes Metab Res Rev 2006; 22:341-347.
45. Tsiotou AG, Sakorafas GH, Anagnostopoulos G, Bramis J. Septic shock; current pathogenetic concepts from a clinical perspective. Med Sci Monit 2005; 11:RA76-RA85.
46. Van den Berghe G, Schoonheydt K, Becx P, et al. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 2005; 64:1348-1353.
47. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449-461.
48. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367.
49. Pickkers P, Jansen Van Rosendaal AJ, Van Der Hoeven JG, Smits P. Activation of the ATP-dependent potassium channel attenuates norepinephrine-induced vasoconstriction in the human forearm. Shock 2004; 22:320-325.
50. Evgenov OV, Pacher P, Williams W, et al. Parenteral administration of glipizide sodium salt, an inhibitor of adenosine triphosphate-sensitive potassium channels, prolongs short-term survival after severe controlled hemorrhage in rats. Crit Care Med 2003; 31:2429-2436.
51. Maybauer DM, Salsbury JR, Westphal M, et al. The ATP-sensitive potassiumchannel inhibitor glibenclamide improves outcome in an ovine model of hemorrhagic shock. Shock 2004; 22:387-391.
52. Salzman AL, Vromen A, Denenberg A, Szabo C. K. (ATP)-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic shock. Am J Physiol 1997; 272:H688-H694.
53. Szabo C, Salzman AL. Inhibition of ATP-activated potassium channels exerts pressor effects and improves survival in a rat model of severe hemorrhagic shock. Shock 1996; 5:391-394.
54. Singer M, Coluzzi F, O'Brien A, Clapp LH. Reversal of life-threatening, drugrelated potassium-channel syndrome by glibenclamide. Lancet 2005; 365:1873-1875.
55. Wilson AJ, Clapp LH. The molecular site of action of K (ATP) channel inhibitors determines their ability to inhibit iNOS-mediated relaxation in rat aorta. Cardiovasc Res 2002; 56:154-163.
56. Yang XM, Proctor JB, Cui L, et al. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 2004; 44:1103-1110.
57. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003; 83:1113-1151.
58. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33:119-124.
59. Simpson SH, Majumdar SR, Tsuyuki RT, et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006; 174:169-174.
60. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.